DrugsNews.net

Drugs Xagena

The Food and Drug Administration ( FDA ) has approved Otezla ( Apremilast ), oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of patients with moderate to severe plaque pso ...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for treatment of patients with advanced or unresectable melanoma who are no longer responding to ...


The European Commission has granted marketing authorization for Zydelig ( Idelalisib ), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers, chronic lymphocytic leukemia ( ...


RPC1063 is a novel, oral, once daily, specific and potent modulator of the sphingosine 1-phosphate 1 receptor ( S1P1R ) pathway, which is a validated G protein-coupled receptor ( GPCR ) target for the ...


Acute myeloid leukaemia ( AML ) is an aggressive and devastating blood cancer. It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World. The current ...


The FDA ( Food and Drug Administration ) has approved Velcade ( Bortezomib ) for the retreatment of adult patients with multiple myeloma who had previously responded to Bortezomib therapy and relapsed ...


The FDA ( Food and Drug Administration ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Promacta ( Eltrombopag; Europe: Revolade ) in patients with severe aplastic ...


The European Commission ( EU ) has approved the use of Avastin ( Bevacizumab ) in combination with Paclitaxel, Topotecan, or Pegylated liposomal doxorubicin chemotherapy as a treatment for women with ...


The FDA ( Food and Drug Administration ) has granted priority review designation for Ivabradine for the treatment of chronic heart failure ( HF ). Ivabradine is an oral drug that inhibits the If cu ...


The Food and Drug Administration ( FDA ) has approved a supplement to expand the indication for Lumizyme ( Alglucosidase alfa ). Lumizyme manufactured at the 4000L scale is now indicated for all Pompe ...


The FDA ( Food and Drug Administration ) has approved Cerdelga ( Eliglustat ) for the long-term treatment of adult patients with the type 1 form of Gaucher disease, a rare genetic disorder. Gaucher d ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Paracetamol ( Acetaminophen ) poisoning is common worldwide. It is treated with intravenous Acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to ...


A retrospective cohort study has evaluated the effect of anesthesia type on the risk of in-hospital mortality among adults undergoing hip fracture surgery in the United States. Participants were 73 ...


The objective of a study was to describe rates and risk factors for prolonged postoperative use of opioids in patients who had not previously used opioids and undergoing major elective surgery. The ...


Eliquis ( Apixaban ) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Apixaban decreases thrombin generation and blood clot formation. Eliquis is ap ...


Stivarga ( Regorafenib ) has been approved by the European Commission ( EC ) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ( GIST ) who progressed ...


Eylea ( Aflibercept ) injection has been approved by the European Commission for the treatment of visual impairment due to diabetic macular edema ( DME ). Diabetetic macular edema is the leading caus ...


Kalydeco ( Ivacaftor ) is the first medicine to treat the underlying cause of cystic fibrosis in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, Ivacaftor is an oral me ...


Hydroxychloroquine ( Plaquenil ) is indicated for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and malaria ( acute attacks and suppressive treatment ). Hypoglyce ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati